



Twist Bioscience Launches Mouse Exome to Power Genetic Research

June 17, 2019

SAN FRANCISCO--(BUSINESS WIRE)--Jun. 17, 2019-- Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the launch of the Twist Mouse Core Exome Panel, the most comprehensive, up-to-date tool for interrogation of the mouse exome, further enabling genetic research of this important model organism.

"We are pleased to launch our first next-generation sequencing (NGS) product for the research market, which can be used for very specific preclinical research for cancer and other genetic diseases," said Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience. "We offer a variety of specific and custom target enrichment panels for NGS which we can update, iterate and customize quickly due to our proprietary silicon-based DNA synthesis platform. The Twist Mouse Core Exome Panel is our first non-human exome and allows us to reach not only core labs but also independent researchers and scientists."

The mouse is an extremely important model system for studying genetic variation, tumor mutations, and phenotypic outcomes as well as the therapeutic effect of pharmaceutical agents. Twist's mouse panel includes the most comprehensive, up-to-date content available. As genetic variant databases are continuously updated, the Twist Mouse Exome panel is thoughtfully designed and built from the most current databases. When combined with Twist's expanding portfolio of library preparation and enrichment reagents, the complete toolset allows researchers to achieve industry-leading coverage across target regions while optimizing sequencing cost and sample throughput.

For more information about the Twist Mouse Core Exome Panel, please visit our [website](#).

About Twist Bioscience Corporation

Twist Bioscience is a leading and rapidly growing synthetic biology company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The core of the platform is a proprietary technology that pioneers a new method of manufacturing synthetic DNA by "writing" DNA on a silicon chip. Twist is leveraging its unique technology to manufacture a broad range of synthetic DNA-based products, including synthetic genes, tools for next-generation sequencing (NGS) preparation, and antibody libraries for drug discovery and development. Twist is also pursuing longer-term opportunities in digital data storage in DNA and biologics drug discovery. Twist makes products for use across many industries including healthcare, industrial chemicals, agriculture and academic research.

Follow us on [Twitter](#) | [Facebook](#) | [LinkedIn](#) | [YouTube](#)

View source version on businesswire.com: <https://www.businesswire.com/news/home/20190617005198/en/>

Source: Twist Bioscience Corporation

Investor Contact:

Argot Partners
Maeve Conneighton
212-600-1902
maeve@argotpartners.com

Media Contact:

Angela Bitting
925-202-6211
media@twistbioscience.com